Full-Time

Master Data Management Data Architect

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Mid, Senior

Hyderabad, Telangana, India

Category
Data Management
Data & Analytics
Required Skills
AWS
Data Analysis
Requirements
  • Master’s degree and 1 to 3 years of Computer Science, IT or related field experience OR
  • Bachelor’s degree and 3 to 5 years of Computer Science, IT or related field experience OR
  • Diploma and 7 to 9 years of Computer Science, IT or related field experience.
Responsibilities
  • Design, develop, and maintain data solutions for data generation, collection, and processing
  • Collaborate and communicate with MDM Developers, Data Architects, Product teams, Business SMEs, and Data Scientists to design and develop end-to-end data pipelines to meet fast paced business needs across geographic regions
  • Identify and resolve complex data-related challenges
  • Adhere to standard processes for coding, testing, and designing reusable code/component
  • Participate in sprint planning meetings and provide estimations on technical implementation
  • As a SME, work with the team on MDM related product installation, configuration, customization and optimization
  • Responsible for the understanding, documentation, maintenance, and additional creation of master data related data-models (conceptual, logical, and physical) and database structures
  • Review technical model specifications and participate in data quality testing
  • Collaborate with Data Quality & Governance Analyst and Data Governance Organization to monitor and preserve the master data quality
  • Create and maintain system specific master data data-dictionaries for domains in scope
  • Architect MDM Solutions, including data modeling and data source integrations from proof-of-concept through development and delivery
  • Develop the architectural design for Master Data Management domain development, base object integration to other systems and general solutions as related to Master Data Management
  • Develop and deliver solutions individually or as part of a development team
  • Approves code reviews and technical work
  • Maintains compliance with change control, SDLC and development standards
  • Contribute to the design, development, and implementation of data pipelines, ETL/ELT processes, and data integration solutions
  • Collaborate with multi-functional teams to understand data requirements and design solutions that meet business needs
  • Implement data security and privacy measures to protect sensitive data
  • Leverage cloud platforms (AWS preferred) to build scalable and efficient data solutions
Desired Qualifications
  • Expertise in architecting and designing Master Data Management (MDM) solutions.
  • Practical experience with AWS Cloud, Databricks, Apache Spark, workflow orchestration, and optimizing big data processing performance.
  • Familiarity with enterprise source systems and consumer systems for master and reference data, such as CRM, ERP, and Data Warehouse/Business Intelligence.
  • At least 2 to 3 years of experience as an MDM developer using Informatica MDM or Reltio MDM, along with strong proficiency in SQL.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.